Advertisement
Canada markets closed
  • S&P/TSX

    24,224.90
    +152.39 (+0.63%)
     
  • S&P 500

    5,792.04
    +40.91 (+0.71%)
     
  • DOW

    42,512.00
    +431.63 (+1.03%)
     
  • CAD/USD

    0.7293
    -0.0036 (-0.49%)
     
  • CRUDE OIL

    73.44
    +0.20 (+0.27%)
     
  • Bitcoin CAD

    83,402.93
    -2,060.95 (-2.41%)
     
  • XRP CAD

    0.72
    -0.01 (-1.06%)
     
  • GOLD FUTURES

    2,625.40
    -0.60 (-0.02%)
     
  • RUSSELL 2000

    2,200.59
    +5.60 (+0.26%)
     
  • 10-Yr Bond

    4.0670
    +0.0340 (+0.84%)
     
  • NASDAQ futures

    20,439.25
    -24.25 (-0.12%)
     
  • VOLATILITY

    20.86
    -0.56 (-2.61%)
     
  • FTSE

    8,243.74
    +53.13 (+0.65%)
     
  • NIKKEI 225

    39,277.96
    +340.42 (+0.87%)
     
  • CAD/EUR

    0.6664
    -0.0008 (-0.12%)
     

Stocks in play: Oncolytics Biotech Inc

Today issued a corporate update to provide investors with a deeper understanding of recent data and what is expected for 2025. Recent clinical efficacy results from the BRACELET-1 trial in HR+/HER2- breast cancer pave the way for a clinical study designed to support an accelerated approval. Key milestones in gastrointestinal cancer clinical trials are expected in 2025, with potential for new registration-enabling studies. Oncolytics Biotech Inc shares T.ONC are trading up $0.07 at $1.27.

Read: